• StraightUp Resources is a mining acquisition and exploration company with flagship properties in Ontario, Canada, and an expanding international footprint
• Following on the acquisition of aerial digital magnetic survey data last year for its flagship properties, the company is preparing a summer work program that will include analysis of its data, identification of key geological targets, and geophysical sampling including a drill program
• The war Russia launched in Ukraine last month has driven some new interest in gold amid concerns about the war’s potential far-reaching impact as well and the immediate impact on Russia’s and the world economy as a result of growing international sanctions
• The Ontario exploration district where StraightUp’s property options are located has historically produced more than 30 million ounces of gold

The gold market has seen recent fluctuations between “war premium” highs over Russia’s assault on Ukraine and the fallout of expected dollar-supporting policies from the U.S. Federal Reserve (https://ibn.fm/cwVbI), although the resultant inflation fear-mongering appears to be easing somewhat (https://ibn.fm/oOsMh). Through it all, gold has maintained its luster for those who regard it as a solution for uncertain times, particularly Russia’s Central Bank, which has been driven to try to strengthen the country’s financial stability in the wake of serious economic sanctions imposed on Russia by numerous countries because of the war (https://ibn.fm/txwEh). Precious metals explorer StraightUp Resources (CSE: ST) (OTCQB: STUPF) is advancing preparations for its summer 2022 work programs in the company’s optioned greenstone belt properties in Ontario, Canada’s Red Lake Mining District — a historically prolific producer of gold (more than 30 million ounces). The work programs will include drilling of the most significant prospects. StraightUp’s flagship properties include the 4,725-hectare (about 11,675 acres) RLX North site and the adjacent 6,275-acre (about 15,505 acres) RLX South site, plus a newly acquired option to purchase the Ranger/Otter mining project adjacent to RLX North that consists of three claims on 1,234 hectares (3,050 acres). The company has two additional projects — Belanger and Ferdinand, at 2,000 hectares (4,942 acres) and 7,143 hectares (17,651 acres), respectively — stretching northeast along the greenstone belt toward the company’s Bear Head gold project (1,944 hectares, or 4,803 acres) in the neighboring Meen-Dempster Greenstone Belt of the Uchi Subprovince. And StraightUp owns the West Cat mine property in southeastern Nevada in the United States, which has reportedly produced some very rich gold ore in a region drawing new excitement for potential prospects. StraightUp is also reviewing the possibility of acquiring the Mallay silver mine and processing plant in the Lima region of Peru, having recently extended a right of exclusivity agreement (“ROE”) for all outstanding shares in Premier Silver Corp., which owns the mine, according to its March 7 statement on the Ranger/Otter option (https://ibn.fm/lnT1Q). StraightUp’s summer exploration programs will include a review and interpretation of historical data on the RLX projects, compiled with new 2021 data to improve the interpretation effort. Following additional examination of the historical drill core, the company will pursue geological mapping and sampling based on the historical data and new soil analysis techniques, as well as geophysical surveys that re-interpret the historical data and the digital magnetic surveys (“MAGs”) conducted from the air last year, according to an investor presentation the company updated this month (https://ibn.fm/IMP72). Exploration of the Belanger Project also planned this summer will largely follow the outline for the RLX properties, with some variation that reflects a different accumulation of historical data on the site. The company is seeking an additional permit for the RLX properties that will allow greater cutting than what was specified in its June 2020 permits, according to the presentation. “We are pleased to further our position in Ontario’s Red Lake Mining District, especially now, given the rapid acceleration of exploration activity and large cap miners interest in the region,” company President and Director Mark Brezer stated in regard to the Ranger/Otter option. Kinross Gold recently acquired Great Bear Resources’ Sobel Project, which is surrounded by the RLX properties, and Kinross is actively pursuing Great Bear Resources’ other prior assets at a total price of about $1.45 billion. For more information, visit StraightUp Resources’ website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to STUPF are available in the company’s newsroom at https://ibn.fm/STUPF

• Lexaria’s patented DehydraTECH(TM) technology provides faster delivery times, increases bioavailability, increases brain absorption, improves drug potency, reduces administration costs, and masks unwanted flavors
• The epilepsy research will compare the FDA-approved Epidiolex(R) to the company’s proprietary DehydraTECH-CBD formulation
• The global cannabidiol (“CBD”) market had an estimated value of $2.7 billion in 2021 and is expected to reach $111.8 billion by 2030, driven by an increase in demand for CBD use in health and wellness industries

Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW), a global innovator in drug delivery platforms, recently announced that the first phase of its epilepsy research program, EPIL-A21-1, has begun. The research program will assess the seizure-inhibiting activity of cannabidiol (“CBD”) administered via the company’s proprietary DehydraTECH(TM) technology, compared to the only FDA-approved CBD-based seizure medication, Epidiolex(R) (https://ibn.fm/uD9Sa). Epidiolex(R) is the first and only FDA CBD medication for the treatment of seizures associated with two rare forms of pediatric epilepsy — Lennox-Gastaut syndrome and Dravet syndrome. Using DehydraTECH’s advanced drug delivery capabilities, Lexaria hopes to demonstrate superior performance in the research program. The company expects to achieve significant gains in systemic delivery and brain uptake — which have been evidenced and announced from other studies comparing the DehydraTECH 2.0 CBD formulations with concentration-matched controls. Lexaria believes this could improve therapeutic efficacy for multiple conditions of the nervous system, including but not limited to epilepsy. The EPIL-A21-1 research program contains two main studies to be performed in rodents following the first phase — a pilot animal model that has already begun. The main studies are slated to commence in May/June and involve an acute seizure model induced by electrical stimulation and chemically induced seizure models. Lexaria has chosen these models because they were previously selected by other researchers studying the antiepileptic effects of CBD during the Epidiolex formulation. The DehydraTECH-CBD test articles needed to commence dosing have already been manufactured and delivered to the third-party laboratory tasked with completing the research program. Lexaria will release updates on the studies occasionally beginning in Q3, 2022. Lexaria’s DehydraTECH technology is designed for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. Benefits of the DehydraTECH technology include:

• Faster delivery times — subjects begin to feel the effects of the product in minutes
• Increase in bioavailability — the technology is more efficient at delivering products into the bloodstream
• Increased brain absorption — testing suggests that DehydraTECH significantly improves the amount of drug delivered across the blood-brain barrier
• Improved drug potency — more ingested product is made available to the body, requiring lower dosages to achieve the same desired effect
• Reduction in drug administration costs — lower doses translate to lower administration costs
• Masks unwanted taste — the technology eliminates or reduces the need for sweeteners

By leveraging its technology, Lexaria Bioscience can successfully tap into the ever-growing CBD market. The global CBD sector had an estimated value of $2.7 billion for 2021 and is expected to grow at a CAGR of 51% by 2030, reaching a value of $111.8 billion (https://ibn.fm/6sjWu and https://ibn.fm/4LKbw). The increase in demand for CBD use in the health and wellness market is the primary driver of growth. As CBD becomes legal in more regions, it is attracting the attention of e-commerce platforms — with North America dominating the market. The growth can also be attributed to the increased adoption of technology and overall greater investments in research and development opportunities. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Lexaria has received a new patent entitled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof”
• The new patent, granted in Australia, is the first awarded from Lexaria’s 8th patent family and offers IP protection across a total of 9 claims
• Lexaria believes the patent could be meaningful as it seeks to build value
• With the new patent, Lexaria’s IP portfolio has now grown to 24 granted patents worldwide

In his letter to shareholders dated January 27, 2022, Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka documented the company’s expectation that it would receive additional patents in 2022. The expected patents would build on the company’s already solid intellectual property (“IP”) portfolio that expanded severalfold last year when Lexaria was awarded five new patents. The then newly granted patents brought the company’s total to 23 granted patents worldwide as of December 2021 (https://ibn.fm/xSXj1). And in an announcement that fulfills part of the company’s expectations for 2022 as well as expands its impressive IP portfolio even further, Lexaria recently reported it had been awarded a new patent entitled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof” (https://ibn.fm/rlxbH). Granted in Australia, the new patent expands on the company’s international IP rights to apply DehydraTECH(TM) technology to most forms of nicotine, namely sprays, gums, lozenges, pouches, capsules, tablets, and pills. It also covers multiple disparate forms of nicotine, including polymer resins of nicotine, freebase nicotine, and other nicotine complexes. Following the receipt of this most recent patent, which is the first patent awarded from its 8th patent family, Lexaria’s IP portfolio has grown to 24 granted patents; the Australian patent offers IP protection across a total of 9 claims and is set to expire in April 2039. Moreover, according to the company, corresponding patent applications within this patent family are currently pending in other jurisdictions, including the U.S. Lexaria is a global innovator in drug delivery platforms. Its flagship drug delivery technology, DehydraTECH, has been proven, through animal and human studies, to increase bioavailability, brain absorption, and the speed of onset of active pharmaceutical ingredients, as well as mask their unwanted tastes. In one such animal study — the oral nicotine absorption study NIC-A21-1 — whose results were announced in October last year, Lexaria established that DehydraTECH-processed nicotine delivered through the oral pouch product format “required only 2 to 4 minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls” (https://ibn.fm/GvCD1). In earlier studies conducted in 2018, the company also revealed that DehydraTECH improved the peak nicotine delivery as well as the speed at which nicotine was delivered to the bloodstream. Moreover, Lexaria established that DehydraTECH for oral nicotine resulted in higher brain levels of nicotine compared to controls (https://ibn.fm/OBHO8). The studies and their groundbreaking results demonstrate the company’s progress toward improving oral nicotine products. In this regard, the protection offered by the granted patent, Lexaria believes, could contribute substantially toward the company’s ability to build value. Speaking during the Benzinga Global Small-Cap Conference held late last year, George Jurcic, Lexaria’s Head of Investor Relations (“IR”), noted that the company already has a patent granted in Australia to use DehydraTECH-processed cannabidiol (“CBD”) to potentially treat heart disease. “We have a disruptive drug technology with multiple opportunities for success in cannabinoids, nicotine, antivirals, and other active pharmaceutical ingredients,” said Jurcic (https://ibn.fm/ofDsw). Thus, the new Australian patent covering the use of DehydraTECH-nicotine builds on the existing IP protection there and sets the stage for the company to exploit nicotine- and CBD-oriented opportunities within this market. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Eat Well Group forecasts approximately CAD$60 million in revenue for 2021
• It projects $90-$110 million in revenue for the 2022 calendar year, representing a double-digit growth rate for the company
• This growth will be primarily attributed to increased online sales through Walmart’s e-commerce platform, along with sales in brick and mortar stores at Walmart, Loblaws and HEB Grocery
• Eat Well Group also looks to grow its market reach through forging relationships and distribution partnerships with key players in the industry

The 2021 calendar year was successful for Eat Well Investment Group (CSE: EWG) (OTC: EWGFF). Most notably, the company has reaffirmed its forecast of approximately CAD$60 million in revenue, despite the challenges posed by the pandemic, supply chain clogs and the relative newness of its platform. 2021 also marked the year of several acquisitions, notably Belle Pulses, a plant-based ingredients processor, and Sapientia, a plant-based food technology platform. The year also marked Eat Well Group’s OTC listing in the United States to its Canadian Stock Exchange profile. For a company that essentially formed in 2021, it has achieved a lot and hopes to maintain the same momentum in the 2022 calendar year (https://ibn.fm/vjTSY). “Eat Well Group is actually a company that’s very, very young. We just formed in ascension this past August thought it’s been decades in the making, and what it is is a plant-based foods platform company,” noted Mark Aneed, the chief executive officer (“CEO”), president and director of Eat Well Group (https://ibn.fm/vjTSY). Eat Well Group is estimating revenues between $90 million and $110 million in 2022, which will mark a significant double-digit growth rate. This, it projects, will be heavily influenced by the anticipated high online sales through Walmart’s e-commerce platform, coupled with sales in brick and mortar stores such as Walmart, Loblaws and HEB Grocery Company (https://ibn.fm/LbClA). The company also hopes to extend its product range by more acquisitions, having recently acquired 51% ownership of Pata Foods, better known as Amara Organic Foods, with an option to obtain up to 80% if it wishes. In February, Eat Well Group announced securing new capital from a strategic group of investors for mergers and acquisitions (“M&A”) and general working activity for the new year (https://ibn.fm/LbClA) Going forward, Eat Well Group looks to capitalize on its distribution growth in Latin America and South America. Its leadership is confident that the structures set up and the investments made thus far will pay off significantly and help the company achieve its $90-$110 million revenue projections for the 2022 calendar year. So far, the company has customers in over 35 countries worldwide. It hopes to grow this number in the new year through partnerships and distribution relationships with key players in the industry. Its management is confident that this will be a great year for the company, creating even more value for its shareholders. For more information, visit the company’s website at www.EatWellGroup.com. NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF

• Flora Growth’s two late 2021 acquisitions added an estimated $35 million in revenue and $7 million in EBITDA
• Its acquisition of Vessel Brand Inc. is projected to bring $35-$45 million in revenue for the 2022 calendar year
• With these acquisitions, the company, an internationally focused cannabis brand builder with a global distribution platform, stamps its position as an undisputed market and M&A leader

In 2021, Flora Growth (NASDAQ: FLGC) completed its Initial Public Offering (“IPO”) and closed the acquisition of Vessel Brand Inc., a direct-to-consumer (“DTC”) business. The company also formed a joint venture to see the KaLaya brand’s distribution in Latin America (https://ibn.fm/scEDT). So far, the company’s portfolio spans a range of verticals and diverse revenue streams that meet the needs of over 500,000 customers. The brands under its umbrella include Mind Naturals skincare, Vessel Brand Inc. and Stardog Loungewear. Flora Growth prides itself in having brands that prioritize natural ingredients and value-chain sustainability to help consumers restore and thrive. Its portfolio has grown mainly through mergers and acquisitions (“M&As”), a move that defined its 2021 calendar year. Over the entire year, for all sectors and industries, worldwide M&A activity reached $5.9 trillion, representing a 64% growth from 2020 and the highest volume since 1980. In total, there were over 63,000 M&A transactions completed, all in a bid for companies to leverage new avenues for growth amid the pandemic, rising inflation and disrupted supply chains (https://ibn.fm/scEDT). Flora Growth capitalized on this and, with two recent acquisitions, was able to add an estimated $35 million in revenues and $7 million EBITDA. For comparison, back in 2020, the company’s acquisitions generated $28 million in revenue and $7 million in EBITDA (https://ibn.fm/scEDT). Flora Growth has also raised about $35 million in capital and added several key executives, positioning itself for upcoming growth. It is projected that the overall global momentum for M&A activity will continue through the 2022 calendar year, and Flora Growth will be at the forefront of it all. Its selection of companies to merge with or acquire provides a good example of what companies need to consider in approaching M&As. According to the company’s projections, its recent acquisition of Vessel Brand Inc., completed in November 2021, will see $35-$45 million in revenue for the 2022 calendar year (https://ibn.fm/scEDT). Flora Growth’s impressive performance over the years can be attributed to its strategic M&As. As it stands, its aggressive acquisition plan proves to be a sure way to create value for stakeholders and grow a company’s market share, reach, brand equity, and overall value. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

Companies and investors are encouraged to attend the 2022 Virtual Growth Conference being held as a virtual gathering March 28-30, 2022. The Virtual Growth Conference, organized by Maxim Group LLC and hosted by M-Vest, will provide a unique opportunity for attendees to interact with institutional investors and executives from 250+ companies. This year’s gathering will feature leaders from a diverse collection of industry sectors, including biotech, clean energy, electric vehicles, financial services, fintech & REITs, gaming & entertainment, healthcare, healthcare IT, infrastructure, shipping and technology/media/telecom. To RSVP for your virtual seat, visit https://ibn.fm/2022VirtualGrowth The 2022 Virtual Growth Conference kicks off day one at 9:00 a.m. ET, offering two distinct tracks designed to keep attendees engaged and informed throughout the three-day gathering. Presenting companies will participate in fireside chats examining their operations and goals, and seasoned executives will take center stage for thought-provoking roundtable discussions moderated by Maxim research analysts. Conference Highlights

• 250+ participating companies representing a variety of industry sectors
• Live roundtable discussions and Q&A sessions with CEOs
• 30-minute fireside chats with executives from emerging growth companies
• Participation is open exclusively to M-Vest members (free registration option is available)

The Virtual Growth Conference brings all the benefits and face-to-face opportunities of traditional investor gatherings in a convenient virtual format, making it easy for executives, institutional investors and M-Vest members to interact and network without making travel plans. IBN (InvestorBrandNetwork) will be a gold sponsor of the conference and is helping maximize visibility for the event as a whole. Together, the conference’s organizers and sponsors aim to create an atmosphere that fosters business development opportunities and offers insight into emerging companies operating across a wide array of industries. To learn more, please visit https://ibn.fm/2022VirtualGrowth

• In an age where investors are inundated with information and companies struggle to engage investors, SRAX provides an innovative platform for both, complete with due diligence tools, a large investor community and events
• SRAX expects full-year 2022 revenue of $46-$48 million, up 46%-52% over unaudited 2021 revenue

Keeping investors’ attention has historically been hard, but it’s even more difficult today. As we entered the digital age and the flood of information becomes readily available, like the emergence of social media, prevalence of Reg As, and multitude of websites peddling more pump than fact, means keeping investor’s attention is even harder. Squaring the circle for both investors and companies, SRAX (NASDAQ: SRAX) developed and acquired a portfolio of products that maximizes engagement for durable corporate and brand awareness, while delivering transparent insight into companies for investors to perform due diligence. In short, the long-standing dynamic for how investors digest information has changed and that means companies must adapt accordingly. The days of long-winded PowerPoints and keynotes aren’t what investors want anymore. Crisp, precise presentations that provide clarity in a matter of minutes with an opportunity for a deeper dive is the new normal. SRAX is bringing these capabilities to companies and using the power of big data to back it up. Judging by revenue growth, the value is being recognized across the board. SRAX takes a holistic approach to the investor space with its Sequire platform, beginning by helping companies understand and evaluate their current shareholder base. From there, Sequire uses the power of big data analytics to identify trends and devise strategies to retain existing (and acquire more) shareholders. This is accomplished in part by using the innovative tech to track investors’ buying and selling behaviors, subsequently using those insights to engage investors across various marketing channels through highly targeted campaigns. SRAX offers a host of other products that complement the Sequire platform, including conference platforms (brick-and-mortar and digital), education and tools (masterclasses, tools, blogs, circles, subcommunities), networking (an investor community of 9+ million retail and institutional investors), and a community newsletter. In other words, everything that investors look for and public companies need, all in one package. After a covid-inspired pause to in-person conferences in 2020 and early 2021, conference center doors began re-opening late in 2021 and are back in full swing in 2022. That’s good news for the thousands of companies and people that attend LD Micro Conferences, the premier events for small- and micro-cap investors. LD Micro began as a newsletter in 2006 with the sole purpose of being an independent resource to the microcap world, blossoming into the pre-eminent event platform in the space before being acquired by SRAX in September 2020. After nearly two years of virtual events, the LD Micro Conference welcomed back investors and presenters with an in-person event at the Luxe Sunset Bel Air in October 2021 that combined physical and virtual elements to form a truly unique experience whether investors attended in person or not. Which is later accompanied by the LD Micro Invitational held later this year, said to be located in Los Angeles from June 7^th – 9^th, with both in-person or virtual components. According to SRAX management, 2022 is set up to be a transformational year after a solid 2021 in the face of the coronavirus pandemic. For the first quarter of 2022, the fintech company expects revenue of $11.5 million, up 111% versus the year prior quarter. The growth trend is expected to continue, with SRAX providing full year 2022 revenue guidance in the range of $46-$48 million, a rise between 46%-52% over 2021 unaudited revenue. For more information on SRAX Inc., visit www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Mydecine participated in this year’s Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference, and will be at the upcoming Maxim Group’s Virtual Growth Conference
• These conferences represent an opportunity for the company to share its R&D pipeline, patent strategies and ongoing clinical trials
• Mydecine’s management has optimism for the future, as it taps into the growing psychedelics therapeutics and smoking cessation markets

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) has been at the forefront of developing novel psychedelic and non-psychedelic molecules for medical use. Its research and development efforts have focused on compounds that can enable safer and more effective treatments for patients dealing with conditions with unmet needs in mental health and addiction disorders. Since its inception back in 2020, the company has made significant strides, not just in its research but also in its clinical trials. So far, it is the leading and only company in the industry that has an ongoing industry-sponsored clinical trial assessing psilocybin for nicotine addiction. Additionally, it is also pursuing other indications that include but are not limited to PTSD and anxiety. Mydecine got to share these advancements at this year’s Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference as well as Maxim Group’s Virtual Growth Conference. It also walked attendants through its R&D pipeline and patent strategies. The Roth Conference is renowned for its in-person experiences. Their March 2022 conference in Orange Country, California, let over 5,100 attendees in on Mydecine’s operations, providing one-on-one meetings with its management (https://ibn.fm/JG1TS). The 32^nd Oppenheimer & Co. Annual Healthcare Conference, also in March 2022, provided investors with an opportunity to interact with public and private healthcare companies in the healthcare industry, including Mydecine. The conference’s goal was to showcase nearly 300 companies that will likely shape the industry for the next decade to come. Mydecine stood out with its first- and second-generation novel therapeutics focusing on psychedelic compounds (https://ibn.fm/AoVdf). The other March 2022 conference is Maxim Group’s Virtual Growth Conference (March 28-30), offering attendees a unique opportunity to interact with executives and institutional investors. The virtual event features company presentations, roundtable discussions, fireside chats, and live Q&A with Chief Executive Officers (“CEOs”). In addition, it represents an opportunity for Mydecine’s management to share its progress so far and offer a glimpse into what it has planned for the future (https://ibn.fm/HL2uP). Mydecine, through its research, has positioned itself to capitalize on the opportunities in the industry, particularly with regards to psychedelic medicine for the treatment of mental health and addiction disorders. Already, the psychedelics therapeutics market is projected to be valued at $66.5 billion by 2030, representing a CAGR of 8.2% over the forecast period. Additionally, the smoking cessation market is expected to post a CAGR of 16.9% to reach $64 billion by 2026 (https://ibn.fm/EWDWA) Mydecine’s management is confident that with the investments made so far, coupled with the plans for the future, the company will capitalize on the industry’s growth, achieve significant progression and create value for its shareholders. For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• Flora Growth is a cannabis cultivator and distributor operating a 100-hectare (about 247-acre) harvesting site called Cosechemos in central Colombia’s favorable growing climate
• Flora Growth has completed its first import of CBD-containing food and beverage products into the United States under its Mambe brand, thanks to Colombian regulatory changes in recent months allowing cannabis product exports
• Flora has filed licenses for 23 cannabinoid-infused food and beverage products with Colombia’s INVIMA food and drug regulatory body
• Imported Flora products will take advantage of the company’s U.S. distribution network customer database, which nearly doubled with last month’s acquisition of established CPG brand JustCBD
• JustCBD has over 300 products, 300,000 customers, and a network of over 14,000 stores across the United States and Flora’s operations will increase its capacity for international growth

The recently announced successful import of Mambe CBD-containing food and beverage products into the United States from Colombia marks a huge step for cannabis cultivator Flora Growth (NASDAQ: FLGC) in the company’s plans for becoming a global market distributor. Flora Growth’s 100-hectare (about 247-acre) Cosechemos cannabis cultivation site in central Colombia is key to its strategy, drawing on ideal conditions for cannabis production that include over 12.5 hours of natural sunlight 365 days a year, a labor force with substantial agricultural experience, and a government that is increasingly friendly to cannabis production and transportation as an outgrowth of years-long drug wars eradication efforts. Colombian President Ivan Duque green-lighted legalization of dried cannabis flower production and exports last July for food, textile and medicinal purposes, while resisting any effort to supply the recreational use market (https://ibn.fm/ne65L). Late last month, Duque signed a resolution that provides the necessary regulatory framework for cannabis product use and export to formalize the development (https://ibn.fm/cmhaL). “We are thrilled to be the first Colombian cannabis operator to capitalize on the law change President Duque signed into effect,” Flora Growth CEO Luis Merchan stated after announcing completion of the U.S. import of its products (https://ibn.fm/uwAR9). “Our team anticipated this regulatory update and has been laying the necessary foundation to expand this new supply chain pathway allowing Flora to quickly bring our diverse product portfolio and low-cost cannabis inputs to new high-growth international markets.” Flora has filed licenses for 23 cannabinoid-infused food and beverage products with Colombia’s food and drug regulatory body, the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), including juices, sparkling seltzers, gummies, chocolates, ghee butter and healthy snack foods that prioritize natural ingredients and value-chain sustainability (https://ibn.fm/rHHVU). Flora anticipates expanding Cosechemos-sourced non-psychoactive flower and derivatives distribution during the coming months as a result of its acquisition of JustCBD, which was announced Feb. 28. JustCBD has an extensive network of over 14,000 stores with over 300,000 customers, boosting Flora’s overall database to more than 500,000 customers, and Flora states it expects JustCBD’s financial performance to immediately contribute to the company’s 2022 revenues and earnings. On March 2, the company announced that its Vessel brand had signed an agreement with JustCBD-affiliated Speedy Distribution that will introduce Vessel’s vape and dry herb products into traditional smoke shop channels (https://ibn.fm/WysA3). “We see this agreement as the first of many where we leverage JustCBD’s existing distribution network and Flora’s diverse product portfolio to amplify growth for our combined Company,” JustCBD CEO Hussein Rakine stated at the time. At the same time, the acquisition is expected to give JustCBD a boost for expansion from its U.S. base into international arenas where CBD products are permissible, including Germany, Mexico, and Colombia, the company states. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• The Bloombox Club subsidiary of PlantX now offers e-commerce platform services in Austria, the United States, the United Kingdom, and Germany for house plant home delivery services
• PlantX currently offers over 5,000 plant-based and vegan products to consumers online and around the world
• Educational material can be found online through the PlantX blog, YouTube Channel, and Recipe Guides

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), a one-stop-shop for plant-based items, through its wholly-owned subsidiary Bloomboxclub Limited, is announcing the launch of its Bloombox Club e-commerce platform expansion into Austria. The Bloombox Club broadens the scope of the PlantX subsidiary’s indoor plant selling business, operating in Austria, the United States, the United Kingdom, and Germany. “Our goal is to have the Austrian Bloombox Club e-commerce platform provide similar customer experiences across the brand. We are confident that this latest e-commerce platform will be successful,” PlantX Founder Sean Dollinger said, commenting on the Austrian launch (https://ibn.fm/0iIjo). Lorne Rapkin, CEO of PlantX, said the company was beyond pleased with the welcoming reception among its consumer base in Austria, as well as the immediate feedback received after the e-commerce site went live. “As we look ahead to the future, we are committed to capitalizing on this growth market opportunity by prioritizing customer satisfaction as we continue to share the Bloombox Club experience with our Austrian community.” The Bloombox Club e-commerce platform in Austria can be accessed at https://bloomboxclub.at/. PlantX and its Bloombox Club subsidiary promote a calmer, happier, and healthier atmosphere through the use of plants. There are scientific and medical benefits to purchasing plants for indoor use – which Bloombox Club is delivering right to the door of each consumer. One of the categories of plants for sale is “air-purifying” indoor plants. These types of plants can help remove chemicals and substances from the air around you, including carbon dioxide, formaldehyde, benzene molecules, nitrogen oxides, and sulfur oxides. As described in a PlantX blog, some of the best plants are Lucky Bamboo, Dragon Tree, Pothos, Spider Plant, Janet Craig, and Snake Plant (https://ibn.fm/ZEYsD). In addition to air-purifying plants, the Bloombox Club website also offers pet-friendly plants. Anyone with a pet knows how bringing something new into the home can pique their interest and, ultimately, their appetites. Keeping a pet-friendly plant in the home can reduce the number of vet visits due to ingesting a potentially fatal house plant. As of Q3 2021, PlantX offers over 5,000 products, all of which support the plant-based community. With categories including XGroceries, XBeverages, XFitness, XBeauty, XRecipes, and XGifts – the company is building a community that supports and increases the knowledge of plant-based living. PlantX offers multiple educational resources for site visitors and customers, including its podcasts, blog, and YouTube channel. The plant-based blog is a wealth of information for tips and tricks (and what it is like) to live a plant-based, vegan lifestyle. With titles like “Things That Should Be In The Vegan Pantry” and “Top 10 Indoor Plants You Can Easily Take Care Of”, readers can learn about living their best plant-based life while also filling the spaces in their homes with plants they aren’t likely to kill off. In addition to the blog, the PlantX website and YouTube Channel overflow with recipe options – making vegan dining much easier, even for a novice joining the community. No matter your plant-based living skill level, PlantX provides the options and the opportunities necessary to make living the lifestyle affordable, knowledgeable, and simple. PlantX puts all of the resources right at your fingertips. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF